Wire reports frame review as high-stakes first hurdle
5 Today 9:22 AM · 14h ago · 4 articles · 1 post · 2 sources · development 5 of 6
AP wire coverage describes the panel review as the first major U.S. regulatory hurdle for a blood test designed to hunt signs of multiple cancers in healthy people by detecting DNA fragments shed by tumor cells.
Grail Inc. Maker of the Galleri multi-cancer blood testFDA Molecular and Clinical Genetics Panel Independent advisory panelVinay Prasad Former FDA biologics chiefWSJ Editorial Board Opinion commentator
The whole story articlesposts the bright band is this development · numbered dots are the others · click one to jump
What was reported 1 claim about this development
-
first by Chicago Tribune, 6h ago · also STAT News, NPR, Baltimore Sun, Mercury News, Orlando Sentinel, Philadelphia Inquirer
2 more headlines
What people said 1 voice · verbatim
-
Get the most important and interesting news from the global economy delivered to your inbox. https:// qz.com/fda-advisers-grail-gall eri-multicancer-blood-test-092326?utm_source=flipboard&utm_medium=activitypub Posted into Business News @ business-news-quartz
All 6 developments of FDA panel votes on Grail's Galleri multi-cancer blood test →
NewswiresGoogle NewsMastodon